The CYP3A4*1B (T/T) and CYP3A5*3 (C/C) genotypes significantly improved the serum triglyceride (TG) level (P < 0.05) and elevated the TB level (P < 0.001). Atorvastatin plasma levels were greater in CYP3A4*1B (T/T) (P < 0.05) and CYP3A5*3 (C/C) (P <...
respectively. TheCYP3A4*1B(T/T) andCYP3A5*3(C/C) genotypes significantly improved the serum triglyceride (TG) level (P < 0.05) and elevated the TB level (P < 0.001). Atorvastatin plasma levels were greater inCYP3A4*1B(T/T) (P < 0.05) andCYP3A5*3(C/C) (P <...
Subgroup analyses by cancer type showed that the G allele and G carrier (AG + GG) of CYP3A4*1B polymorphism had significant associations with increased risk of prostate cancer, but not with breast cancer, leukemia, or other cancers. With further subgroup analysis based on different ...
Published by De Gruyter June 1, 2005 CYP3A4*1B and NAT2*14 Alleles in a Native African Population Isa Cavaco , Rita Reis , J. Pedro Gil and Vera Ribeiro From the journal Clinical Chemistry and Laboratory Medicine (CCLM) https://doi.org/10.1515/CCLM.2003.091...
Published by De Gruyter June 1, 2005 CYP3A4*1B and NAT2*14 Alleles in a Native African Population Isa Cavaco , Rita Reis , J. Pedro Gil and Vera Ribeiro From the journal Clinical Chemistry and Laboratory Medicine (CCLM) https://doi.org/10.1515/CCLM.2003.091...
CYP450 3A4 (CYP3A4), encoded by the =0.001; recessive model: OR=1.77, 95 %CI: 1.30–2.41, =0.004). Subgroup analyses by cancer type showed that the G allele and G carrier (AG+GG) of CYP3A4*1B poly...
CYP3A4*1B polymorphism and cancer risk: a HuGE review and meta-analysis. Tumour Biol J Int Soc Oncodevelopmental Biol Med. avr 2013;34(2):649-60... LP Zhou,F Yao,H Luan,... - 《Tumour Biology the Journal of the International Society for Oncodevelopmental Biology & Medicine》 被引量...
Significant differences in weight-adjusted dose (p = 0.007) and a trend in Co/dose (p = 0.056) were found between CYP3A4*1B allele carriers and non-carriers. Figure 2 and Figure 3 show plots of weight-adjusted dose and Co/dose for the two groups of CYP3A4 genotypes (rs2740574). ...
1、在体内不经CYP3A4代谢的药物是()。【单选题】 A. 氟伐他汀 B. 普伐他汀 C. 阿托伐他汀 D. 瑞舒伐他汀 E. 洛伐他汀
二氢吡啶类钙通道阻滞剂的基本结构如下图,二氢吡啶是该类药物的必须药效团之一,二氢吡啶类钙通道阻滞剂代谢酶通常为CYP3A4,影响该酶活性的药物可产生各药物相互作用,钙通道阻滞剂的代表药物是硝苯地平。 问题1.西咪替丁与硝苯地平合用,可以影响硝苯地平的代谢,使硝苯地平代谢速度 A.代谢速度不变...